Please login to the form below

Not currently logged in
Email:
Password:

Raffi Asadorian joins AcelRx Pharmaceuticals

He moves from biotech firm Amyris to take up chief financial officer role

Raffi AsadorianSpeciality pharmaceutical company AcelRx Pharmaceuticals has appointed Raffi Asadorian as its new chief financial officer.

He has over 25 years’ experience in finance, strategy and corporate development and was most recently chief financial officer at commercial-stage biotech company Amyris.

Asadorian said: “This is an exciting time to join AcelRx, especially with multiple upcoming milestones in the US and EU that have the potential to transform the company.

“It’s clear that the company has an experienced management team and a robust portfolio of late stage assets. I look forward to contributing to this dynamic organisation and its growth.”

Prior to joining Amyris, Asadorian was the CFO for Asa, a private equity-owned medical diagnostics company where he led finance, corporate development and investor relations.

He has also held roles at PircewaterhouseCoopers and Barr, which was later acquired by Teva Pharmaceuticals.

Vince Angotti, chief executive officer at AcelRx, said: “I am thrilled to have Raffi join our team. He is an accomplished financial executive who has held leadership roles in large multinational, specialty pharmaceutical and life sciences companies.”

1st August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics